PharmaCyte Biotech, Inc. filings document the company's public-company reporting, capital structure and governance as a Nasdaq-listed biotechnology issuer with common stock registered under PMCB. Recent disclosures include 8-K material-event reports, proxy statements for stockholder votes, equity incentive plan amendments, securities issuance authorizations, preferred stock and warrant financing terms, and notices related to periodic reporting.
The filings also document material agreements tied to external investments and capital deployment, alongside shareholder voting mechanics and security-structure disclosures for common stock, convertible preferred stock and warrants.
PharmaCyte Biotech, Inc. (PMCB) filed an S-3 shelf registration to register shares issuable upon conversion of Series C Preferred Stock and upon exercise of outstanding warrants and placement agent warrants. The prospectus notes the company would receive up to approximately $7.5 million only if all warrants are exercised for cash; otherwise selling stockholders will receive proceeds from secondary sales. The registration covers shares held by multiple institutional and individual selling stockholders (many pegged at 4.99% ownership thresholds) and includes a 150% sizing convention used to calculate maximum conversion and warrant share counts. The document reiterates significant risks including a clinical hold interaction with the FDA on an IND for a planned LAPC clinical trial, long drug-development timelines, dependence on third parties, potential illiquidity, and general regulatory and competitive risks. The offering may enable secondary liquidity but also creates potential dilution if conversions/exercises occur.
PharmaCyte Biotech, Inc. entered into a Securities Purchase Agreement for a private placement of 7,000 shares of new Series C convertible preferred stock with a stated value of $1,000 per share, for expected gross proceeds of $7 million. The preferred stock is initially convertible at $1.00 into up to 7,000,000 shares of common stock and is accompanied by warrants to purchase up to 7,000,000 additional common shares at an exercise price of $1.00, both with anti-dilution adjustments.
The preferred carries a 7% annual cash dividend, increasing to 15% upon certain Triggering Events, and votes with common stock based on stated value divided by the then-current conversion price, subject to Nasdaq “Minimum Price” constraints. Issuance above 19.99% of outstanding common stock requires Nasdaq stockholder approval, which the company plans to seek at a meeting no later than October 31, 2025. PharmaCyte will file a resale registration statement for 150% of the conversion shares and 150% of the warrant shares and may owe liquidated damages if it misses registration milestones.